Trial · NCT02564744
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1: Safety Run-in | 17 | |
| Overall Study | STARTED | Part 1: Cohort 1 | 8 | |
| Overall Study | STARTED | Part 1: Cohort 2 | 12 | |
| Overall Study | STARTED | Part 2/3: Cohort A | 33 | |
| Overall Study | STARTED | Part 2/3: Cohort B | 30 | |
| Overall Study | Efficacy Evaluable (EE) Population | Part 1: Safety Run-in | 15 | |
| Overall Study | Efficacy Evaluable (EE) Population | Part 1: Cohort 1 | 8 | |
| Overall Study | Efficacy Evaluable (EE) Population | Part 1: Cohort 2 | 11 | |
| Overall Study | Efficacy Evaluable (EE) Population | Part 2/3: Cohort A | 30 | |
| Overall Study | Efficacy Evaluable (EE) Population | Part 2/3: Cohort B | 30 | |
| Overall Study | Pharmacokinetic (PK) Population | Part 1: Safety Run-in | 17 | |
| Overall Study | Pharmacokinetic (PK) Population | Part 1: Cohort 1 | 8 | |
| Overall Study | Pharmacokinetic (PK) Population | Part 1: Cohort 2 | 12 | |
| Overall Study | Pharmacokinetic (PK) Population | Part 2/3: Cohort A | 32 | |
| Overall Study | Pharmacokinetic (PK) Population | Part 2/3: Cohort B | 29 | |
| Overall Study | Anti-drug Antibody (ADA) Population | Part 1: Safety Run-in | 14 | |
| Overall Study | Anti-drug Antibody (ADA) Population | Part 1: Cohort 1 | 6 | |
| Overall Study | Anti-drug Antibody (ADA) Population | Part 1: Cohort 2 | 10 | |
| Overall Study | Anti-drug Antibody (ADA) Population | Part 2/3: Cohort A | 30 | |
| Overall Study | Anti-drug Antibody (ADA) Population | Part 2/3: Cohort B | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02564744/flow